Heinz Ludwig

Research interests

Publications

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0876-z

• International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30309-2

• The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

  Nature Reviews Nephrology · 2018 · 10.1038/s41581-018-0077-4

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx096

• Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30578-8

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.65.0044

• European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

  Haematologica · 2015 · https://doi.org/10.3324/haematol.2014.117176

• Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

  Blood · 2015 · 10.1182/blood-2014-12-615187

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00464-7

• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1402551

• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1411321

• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

  Blood · 2011 · 10.1182/blood-2010-10-299487

• Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

  Blood · 2011 · 10.1182/blood-2010-10-299529

• Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2010.30.8791

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Leukemia · 2010 · 10.1038/leu.2010.60

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · 10.1038/leu.2008.307

• Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.20.8397

• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  Leukemia · 2007 · 10.1038/sj.leu.2405062

• International uniform response criteria for multiple myeloma

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404284

• International Staging System for Multiple Myeloma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.04.242

• The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

  European Journal of Cancer · 2004 · 10.1016/j.ejca.2004.06.019

• Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

  The Hematology Journal · 2003 · 10.1038/sj.thj.6200312

• The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, andmdr gene expression in colorectal cancer

  Cancer · 1993 · 10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2

• Erythropoietin Treatment of Anemia Associated with Multiple Myeloma

  New England Journal of Medicine · 1990 · 10.1056/nejm199006143222402

Current projects

No projects listed.